CTLA4 and melanoma: Ipilimumab, a specific monoclonal antibody targeting CTLA-4, interacts with primary NK cells, IL-2-activated NK cells, and γδT cells via FcγRIIIA receptors, thereby triggering antibody-dependent cell-mediated cytotoxicity (ADCC) responses against CTLA-4-expressing melanoma cell lines and tissues [31].